Results 61 to 70 of about 18,044 (151)

Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months ...
Mikel Gurrea‐Rubio, Laura A. Cooney, Kohei Maeda, Phillip L. Campbell, Qi Wu, Camila I. Amarista, Alexander Stinson, Ray Ohara, Yang Mao‐Draayer, Michael L. Whitfield, Shiv Pillai, Poulami Dey, Johann E. Gudjonsson, Pei‐Suen Tsou, Dinesh Khanna, David A. Fox   +15 more
wiley   +1 more source

Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry

Arthritis &Rheumatology, EarlyView.
Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti, Francesca Motta, Liala Moschetti, Cosimo Bruni, Carina Mihai, Claudia Iannone, Maria Rosa Pellico, Stefano Stano, Stefano Erba, Claudia Barison, Eleonora Pazzi, Andrea Benini, Beatrice Moccaldi, Kurszán Jász Dávid, Ágnes Ágoston‐Szabó, Beatrice Gabrielli, Francesca Nava, Dóra Tari, Francesca Romana Di Ciommo, Yuri Sasaki, Gonçalo Boleto, Radim Bečvář, Alejandro Brigante, Britta Maurer, Massimiliano Limonta, Rahma A. Elziaty, Fabiola Atzeni, Lilian Maria López Núñez, Roberta Foti, Francesco Benvenuti, Brigitte Granel, Elena Rezus, Leila Caillault, Sophie Blaise, Cristiana Sieiro Santos, Fabio Cacciapaglia, Roberto Giacomelli, Rossella De Angelis, Serena Guiducci, Duygu Temiz Karadag, Gabriella Szűcs, Luca Idolazzi, Gábor Kumánovics, Florenzo Iannone, Maurizio Cutolo, Gianluca Moroncini, Valeria Riccieri, Nicoletta Del Papa, Elisabetta Zanatta, Oliver Distler, Masataka Kuwana, Carlo Selmi, Maria De Santis   +52 more
wiley   +1 more source

Nail Disorders in Systemic Conditions

JEADV Clinical Practice, EarlyView.
ABSTRACT Nail findings in children can be indicative of an underlying systemic disease. Many of these findings are seen in multiple entities and are not specific to one disease. The importance of specifically examining for these nail changes cannot be overstated.
Jane Sanders Bellet
wiley   +1 more source

Morphoea with Myositis: A Rare Association

Case Reports in Rheumatology, 2011
In this case, we describe an unusual presentation of a young woman with a rash typical of morphoea (confirmed on biopsy), who went on to develop myositis in an atypical distribution.
Mary Sommerlad, Richard Bull, Claire Gorman   +2 more
doaj   +1 more source

Telangiectasia in Systemic Sclerosis Is a Marker of Increased Disease Morbidity and Mortality: Analyses From the Australian Scleroderma Cohort Study

Australasian Journal of Dermatology, EarlyView.
ABSTRACT This Australian retrospective cohort analysis of 1977 patients investigates and expands on correlates of telangiectasia in systemic sclerosis to determine whether this cutaneous sign is a potential surrogate marker for disease progression and prognosis.
Vivien Wai Yun Lai, Dylan Hansen, Maryam Tabesh, Jessica Fairley, Laura Ross, Nava Ferdowsi, Gene‐Siew Ngian, Diane Apostolopoulos, Joanne Sahhar, Lauren V. Host, Jennifer Walker, Gabor Major, Susanna Proudman, Wendy Stevens, Mandana Nikpour, Amanda M. Saracino   +15 more
wiley   +1 more source

Survival among patients with systemic sclerosis‐associated pulmonary arterial hypertension in the Australian scleroderma cohort study

Internal Medicine Journal, EarlyView.
Abstract Background and Aims Systemic sclerosis (scleroderma; SSc) patients can develop pulmonary arterial hypertension (PAH), which is a leading cause of death. We sought to evaluate severity, therapeutic strategy and survival of SSc‐PAH in the Australian Scleroderma Cohort Study (ASCS).
Zoe Brown, Dylan Hansen, Kathleen Morrisroe, Nava Ferdowsi, Laura Ross, Wendy Stevens, Maryam Tabesh, Joanne Sahhar, Gene‐Siew Ngian, Diane Apostolopoulos, Kimti Kumar, Jennifer G. Walker, Susanna Proudman, Mandana Nikpour   +13 more
wiley   +1 more source

Management of Non‐Plaque‐Induced Gingival Conditions: A Systematic Review—Part 2: Inflammatory and Immune Conditions; Neoplasms; and Gingival Pigmentation

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra, Cecile Wasielewski, Bruno Špiljak, Maja Sabalić‐Schoener, Sebastien Jungo, Ivan Alajbeg   +5 more
wiley   +1 more source

Restoring Mouth Opening in Systemic Sclerosis: A Scoping Review of Interventions

Oral Diseases, EarlyView.
ABSTRACT Objectives To map and characterize the therapeutic strategies described in the literature for the management of microstomia in patients with systemic sclerosis. Methods This scoping review was conducted in accordance with the PRISMA‐ScR guidelines. Searches were performed in Medline/PubMed, Embase, Scopus, Web of Science, Cochrane Library, and
Beatriz Borba Barros Bernardo, Lucas Nascimento Ribeiro, Luiz Alcino Monteiro Gueiros, Belmiro Cavalcanti do Egito Vasconcelos, Sandra Lúcia Dantas Moraes, Marianne Vasconcelos Carvalho   +5 more
wiley   +1 more source

Anti‐U1‐RNP‐Positive Inflammatory Myopathy Presenting With Dysphagia: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT High‐titer anti‐U1‐RNP antibodies may present with myopathy without fulfilling MCTD criteria. We report a 38‐year‐old woman with proximal weakness, elevated muscle enzymes, anti‐U1‐RNP positivity, and inflammatory myopathy on EMG/MRI, but lacking classic overlap features.
Anjlee, Sana Rasheed, Moosa Ashfaq, Simran Bai, Ali Jan Yaqubi, Ahmed Asad Raza   +5 more
wiley   +1 more source

Nintedanib in systemic sclerosis treatment: a case report

Journal of Medical Case Reports
Background Nintedanib was approved for the treatment of scleroderma and scleroderma-related interstitial lung disease, as it decrease the forced expiratory volume. Case presentation A 48-year-old Asian female patient with systemic scleroderma 6 years ago
Maysoun Kudsi, Raghad Tarcha, Naram Khalayli   +2 more
doaj   +1 more source